BRAF V600EPost-hoc analysisESMO 2025來源:人工整理
1L EC+mFOLFOX6 → subsequent tx
關鍵結果PFS2: 20.7 vs 12.9 mo (sequential EC)
一線即用 EC+化療 > 序貫式先化療再 EC。「最佳治療優先」獲證實
詳細證據整理
Subsequent Therapies in the Phase 3 BREAKWATER Study of First-Line EC + mFOLFOX6 in Patients with BRAF V600E-Mutant mCRC
Key Findings
Subsequent Therapy in the Control Arm
- 71.9% of control arm patients received a subsequent BRAF inhibitor-based therapy
- 55.4% of control arm patients received encorafenib + cetuximab (EC) as subsequent therapy
PFS2 (Progression-Free Survival After Next Line of Therapy)
| Measure | EC+mFOLFOX6 (1L) | Control → EC (1L→2L) |
|---|---|---|
| Median PFS2 | 20.7 months | 12.9 months |
These data demonstrate that first-line use of EC+mFOLFOX6 results in superior cumulative disease control compared to the strategy of using chemotherapy first and reserving EC for the second line.
Surgical Conversion
- Surgical conversion rate with EC+mFOLFOX6: 5.2%
- Complete resection rate: 3.0%
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…